Clinical trials: Influenza Virus Infection
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04
This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.
- Trial name
- NCT00814385
- Testing
- Aflunov (Single prime, single boost), Aflunov (Double prime, single boost), Aflunov (No prime, single boost)
- Where
- 2 sites in United Kingdom
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Flu
Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults
This is a phase 1, research study is looking at the safety and acceptability of a new vaccine adjuvant (immune booster) called PAL when combined with the seasonal flu vaccine (Fluviral) to test the safety and effectiveness of new…
- Trial name
- NCT02188810
- Testing
- PAL, TIV
- Where
- Canada
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Folia Biotech Inc.
Flu
Quantification of Viral Load in the Upper Respiratory Tract in Patients Treated With Olsetamivir for Influenza
Seasonal influenza is a frequent disorder with high impact on morbidity and mortality and significant burden on healthcare-related cost.
- Trial name
- VIRIDAE (NCT04515446)
- Testing
- Rapid test for diagnosis orientation, quantitative PCR
- Where
- Monaco
- Volunteers
- 18 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Influenza
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
This research will study safety and the body's immune (defense system) responses, including anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated influenza "H5" bird flu, virus vaccine.
- Trial name
- NCT00912496
- Testing
- MF-59, A/Anhui/05
- Where
- 10 sites in United States
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Vial INJ.) administered as a single intramuscular injection
- Trial name
- NCT02111070
- Testing
- IL-YANG FLU Vaccine
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Influenza
Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza
This Phase 2 protocol is designed to compare two dose levels of laninamivir octanoate versus placebo. The objectives are to obtain safety and efficacy in adults aged 18 to 64 years who present to clinic with symptomatic…
- Trial name
- Igloo (NCT01793883)
- Testing
- 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate
- Where
- 221 sites in United States, Australia and 14 more
- Volunteers
- 639 people
- Sponsor
- Biota Scientific Management Pty Ltd
Healthy
A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health
The purpose of this study is to demonstrate the non-inferiority of the concomitant administration of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) and…
- Trial name
- NCT03339713
- Testing
- Ad26.RSV.preF, Fluarix
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Respiratory Viral Infection
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected…
- Trial name
- RESPIRE (NCT07633288)
- Testing
- AP1189, 100 mg
- Where
- 11 sites in Bosnia and Herzegovina, Montenegro and 2 more
- Volunteers
- 96 people
- Sponsor
- SynAct Pharma Aps
Influenza
TIV and High Dose TIV in Subjects With Rheumatoid Arthritis
A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched control subjects .
- Trial name
- NCT01436370
- Testing
- Trivalent inactivated influenza vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Severe Influenza, Intensive Care (ICU)
Early Corticosteroids in Severe Influenza Pneumonia
This is a Phase III, multicentre, randomized, controlled, double-blind, superiority trial aiming to evaluate the efficacy of dexamethasone versus placebo in patients admitted to intensive care or intermediate care with influenza…
- Conditions
- Severe Influenza, Intensive Care (ICU), Reanimation, Infectious Diseases
- Trial name
- ECSIP (NCT07786662)
- Testing
- Dexametasone
- Where
- 48 sites in France
- Volunteers
- 544 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Influenza, Human
Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015
The purpose of this study is to assess the prevalence, strain circulation and disease burden of seasonal Influenza A and B in Panama, selected countries of Central America and the Caribbean from the Year 2010 to 2015.
- Trial name
- NCT02885246
- Testing
- Data collection
- Where
- Panama
- Volunteers
- 1,839 people
- Sponsor
- GlaxoSmithKline
Covid19, Influenza A
Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19
The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020.
- Conditions
- Covid19, Influenza A, Respiratory Disease
- Trial name
- AtemNHK (NCT04653727)
- Testing
- Cross-sectional survey
- Where
- Germany
- Volunteers
- 1,287 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Pneumonia
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin…
- Trial name
- RECOVERY (NCT04381936)
- Testing
- Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine
- Where
- 16 sites in Belgium, Estonia and 14 more
- Volunteers
- 70,000 people
- Sponsor
- University of Oxford
Influenza
Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults
1. To assess the safety, reactogenicity, tolerability, and adverse events (AEs) of the VAX102 vaccine in a two dose regimen (Day 0 and Day 28) at the 1.0 µg dose level delivered i.m., or the 2.0 µg dose level delivered s.c.
- Trial name
- NCT00921947
- Testing
- VAX102
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VaxInnate Corporation
Influenza
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle).
- Trial name
- NCT00310206
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Response
Open-Label Influenza Vaccine Evaluation
This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons.
- Trial name
- OLIVE (NCT02872311)
- Testing
- High Dose Influenza vaccine, Adjuvanted Influenza vaccine, Standard Dose Influenza vaccine
- Where
- United States
- Volunteers
- 179 people
- Sponsor
- Marshfield Clinic Research Foundation
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Behavior and Behavior Mechanisms
Nationwide Utilization of Danish Government Electronic Letter System for Increasing InFLUenza Vaccine Uptake
In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations.
- Trial name
- NUDGE-FLU (NCT05542004)
- Testing
- Behavioral Economic Principles
- Where
- Denmark
- Volunteers
- 964,870 people, healthy volunteers welcome
- Sponsor
- Tor Biering-Sørensen
Influenza
Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents
The present study is the first study designed to evaluate safety, tolerability and immunogenicity of the cell culture-derived influenza vaccine in healthy children and adolescents aged 3 to 17 years.
- Trial name
- NCT00645411
- Testing
- Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
- Where
- 60 sites in United States, Croatia and 5 more
- Volunteers
- 3,604 people, healthy volunteers welcome
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.